ImmunityBio, Inc. (IBRX) witnessed a significant pre-market surge of 5.23% on Friday, driven by investor enthusiasm over the company's plans to submit multiple treatments for approval by the U.S. Food and Drug Administration (FDA) in 2025.
The biopharmaceutical company announced that it would file a supplemental biologics license application (BLA) for the treatment of bladder cancer. If approved by the FDA, this BLA would allow ImmunityBio to commercialize its product across the United States.
Additionally, the company aims to submit another BLA for the treatment of a specific type of lung cancer. Investors were further encouraged by the positive results from a Phase 2B study, which demonstrated the efficacy of ImmunityBio's Anktiva drug in combination with other inhibitors for patients who had failed first and second-line treatment attempts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.